Detalhe da pesquisa
1.
Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study.
Clin Infect Dis
; 68(9): 1522-1529, 2019 04 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-30165431
2.
Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa.
Eur Respir J
; 51(6)2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29724920
3.
Correspondence regarding "Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa".
Eur Respir J
; 56(1)2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32703820
4.
Responding to SARS-CoV-2 in South Africa: what can we learn from drug-resistant tuberculosis?
Eur Respir J
; 56(1)2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32471936
5.
Implementing a Substance-Use Screening and Intervention Program for People Living with Rifampicin-Resistant Tuberculosis: Pragmatic Experience from Khayelitsha, South Africa.
Trop Med Infect Dis
; 7(2)2022 Jan 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-35202216
6.
Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study.
Lancet Infect Dis
; 22(4): 496-506, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34780706
7.
Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa.
EClinicalMedicine
; 20: 100290, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-32154506
8.
"Life continues": Patient, health care and community care workers perspectives on self-administered treatment for rifampicin-resistant tuberculosis in Khayelitsha, South Africa.
PLoS One
; 13(9): e0203888, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30216368